The Boston Lung Cancer Survival Cohort

波士顿肺癌生存(BLCS)队列是一个超过12,000个肺的癌症流行病学队列 自1992年以来，马萨诸塞州总医院和达纳-法伯癌症研究所登记了癌症病例。 这种丰富的资源使研究人员能够了解肺癌的异质性，已经确定 有价值的预后标记物和刺激新的治疗策略。例如，BLCS支持 首次发现EGFR突变与EGFR-酪氨酸激酶治疗反应之间的关联 抑制剂和有效治疗非小细胞肺癌患者ALK和 ROS1重排。2017年，该队列演变为幸存者流行病学队列，由 U01拨款至2023年5月。我们在第一个U01筹资周期(2017-2022年)取得了实质性进展-我们 已经发表了100多篇论文，资助了6个新的赠款，并与全国50名合作者和 在国际上。随着U01奖项即将到期，迫切需要续签：1)首先保持这一点，并 最全面的肺癌幸存者队列具有最长的随访期-一个无与伦比的来源 用于翻译研究的数据；2)通过自动图像建立创新的、详细的表型数据库 分析高分辨率计算机断层扫描，以及放射组学数据库；3)使已建立的 基础设施，以促进内部和外部调查人员试验方法方法，这些方法将转化为 注重生存和治疗毒性的生产性多学科项目赠款；以及4)利用 Dana-Farber/哈佛癌症中心肺部项目资源，用于创造性的多学科合作 重点关注治疗结果。新的资金对招募2,500个新病例也至关重要(总共 14,500例)到这个已经很大的队列中。新病例至关重要：1)便于比较新病例 日新月异的治疗方法与传统疗法及新的临床研究评价 治疗环境；2)允许我们收集更多具有驱动程序突变数据的病例以及接受治疗的病例 使用免疫检查点抑制剂；3)促进重复生物样本的收集，以支持开发 预测/预测生物标志物；4)使我们能够收集详细的数据，从而能够对环境进行评估 生存的决定因素以及种族和社会经济决定因素；以及5)使我们的研究能够 确定放射学、基因组学、表观遗传学和其他表观生物标志物、环境决定因素和种族 以及与患者生存相关的社会经济决定因素，以指导改进的肺癌筛查 和治疗策略。BLCS是最大的肺癌生存队列之一，包括 丰富的生物标记物，肿瘤分子特征，成像，肺功能，遗传学，表观遗传学，传统 流行病学风险因素和电子健康记录数据。在持续的支持下，这一全面的队列 将提供独特的机会来探索肺癌存活率和治疗结果的预测因素， 催化强大的翻译研究，改善肺癌患者的健康。

The Boston Lung Cancer Survival (BLCS) cohort is a Cancer Epidemiology Cohort of more than 12,000 lung cancer cases enrolled at Massachusetts General Hospital and the Dana-Farber Cancer Institute since 1992. This rich resource enables research to understand lung cancer heterogeneity that has already identified valuable prognostic markers and stimulated new treatment strategies. For example, the BLCS supported the first discovery of the association between EGFR mutations and response to therapy with EGFR-tyrosine kinase inhibitors and enabled research on effective treatments for non-small cell lung cancer patients with ALK and ROS1 rearrangements. In 2017, the cohort evolved into a survivor epidemiology cohort that is sustained by a U01 grant until May 2023. Our progress during the first U01 funding cycle (2017–2022) is substantial—we have published over 100 papers, supported 6 new grants, and worked with 50 collaborators nationally and internationally. With the U01 award expiring soon, there is an urgency to renew to: 1) maintain this first and most comprehensive lung cancer survivor cohort with the longest follow-up period—an unmatched source of data for translational research; 2) establish an innovative, detailed phenotyping database via automated image analysis of high-resolution computed tomography, as well as a radiomics database; 3) enable the established infrastructure to facilitate internal and external investigators to pilot methodologic approaches that will turn into productive multidisciplinary project grants by focusing on survival and treatment toxicity; and 4) leverage the Dana-Farber/Harvard Cancer Center Lung Program resources for creative multidisciplinary collaborations focused on treatment outcomes. Renewed funding is also critical to recruit 2,500 new cases (for a total of 14,500 cases) to this already large cohort. New cases are vitally important to: 1) facilitate comparison of new treatments and traditional therapy as well as evaluation of new clinical investigation in an ever-changing therapeutic environment; 2) allow us to collect more cases with driver mutation data, as well as those treated with immune checkpoint inhibitors; 3) promote collection of repeated biological samples to support developing prognostic/predictive biomarkers; 4) allow us to collect detailed data enabling assessment of environmental determinants as well as racial and socioeconomic determinants of survival; and 5) empower our studies to identify radiomic, genomic, epigenetic, and other phenomic biomarkers, environmental determinants, and racial and socioeconomic determinants that are relevant to patient survival to guide improved lung cancer screening and treatment strategies. The BLCS is one of the largest lung cancer survival cohorts and encompasses a wealth of biomarker, tumor molecular characterization, imaging, lung function, genetic, epigenetic, traditional epidemiologic risk factor, and electronic health record data. With continued support, this comprehensive cohort will provide unique opportunities to explore predictors of lung cancer survival and treatment outcomes, catalyzing powerful translational research that improves the health of individuals with lung cancer.